<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03282474</url>
  </required_header>
  <id_info>
    <org_study_id>HepNet-SofE</org_study_id>
    <secondary_id>2017-000403-24</secondary_id>
    <nct_id>NCT03282474</nct_id>
  </id_info>
  <brief_title>HepNet Pilot Trial: Multicenter Trial for the Treatment of Chronic Hepatitis E With Sofosbuvir (SofE)</brief_title>
  <official_title>HepNet Pilot Trial: Multicenter Trial for the Treatment of Chronic Hepatitis E With Sofosbuvir (SofE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hannover Medical School</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>HepNet Study House, German Liverfoundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>German Center for Infection Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hannover Medical School</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single arm multicenter pilot study to provide preliminary evidence whether
      sofosbuvir (SOF) is efficacious and can be safely used in patients with chronic Hepatitis E
      virus infection.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 7, 2017</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Prospective, open-label, single-arm multicenter, phase II pilot trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects who become HEV RNA negative after 24 weeks of therapy</measure>
    <time_frame>after 24 weeks of therapy</time_frame>
    <description>Measured by the proportion of subjects who become HEV RNA negative (HEV RNA undetectable)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who are HEV RNA negative 12 weeks after discontinuation of therapy</measure>
    <time_frame>12 weeks after discontinuation of therapy (week 36)</time_frame>
    <description>Viral load measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Additional efficacy evaluations include HEV RNA change from baseline during therapy</measure>
    <time_frame>after 2 days, 4 days, 1 week, 2 weeks, 4 weeks, 8 weeks, 12 weeks,16 weeks, 20 weeks, and 24 weeks of therapy</time_frame>
    <description>Viral load and laboratory measurements</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of proportion of patients who are HEV RNA negative after rapid or slow decline of HEV viral load after 24 weeks of therapy</measure>
    <time_frame>after 24 weeks of therapy</time_frame>
    <description>Viral load measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subject who reached ALT normalization after 12 weeks and 24 weeks of therapy and 12 weeks after discontinuation of therapy</measure>
    <time_frame>after 12 and 24 weeks of therapy and 12 weeks after discontinuation of therapy (week 36)</time_frame>
    <description>Laboratory measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of safety: Adverse events and safety laboratory tests will be collected throughout the study</measure>
    <time_frame>through study completion, an average of 36 weeks</time_frame>
    <description>Collection of adverse events and safety laboratory tests</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Hepatitis E</condition>
  <condition>Hepatitis Chronic Viral</condition>
  <arm_group>
    <arm_group_label>Sofosbuvir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sofosbuvir 400 MG film-coated tablet, oral administration of one tablet once daily for 24 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sofosbuvir</intervention_name>
    <description>Sofosbuvir 400 MG Oral Tablet [Sovaldi]</description>
    <arm_group_label>Sofosbuvir</arm_group_label>
    <other_name>Sovaldi</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Willing and able to provide written informed consent

          2. Male or female, age ≥ 18 years

          3. Confirmation of chronic HEV infection documented by: Positive HEV RNA at least 3
             months before Screening, and positive for HEV RNA at the time of Screening

          4. Documented previous ribavirin therapy or documented contraindication for full dose (≥
             600mg qd) ribavirin monotherapy for at least 3 months

          5. Body mass index (BMI) ≥ 18 kg/m2

          6. Screening ECG without clinically significant abnormalities

          7. Subjects must have the following laboratory parameters at screening:

               -  Platelets ≥ 60,000/μL

               -  INR ≤2.0 x ULN unless subject has known hemophilia or is stable on an
                  anticoagulant regimen affecting INR

               -  HbA1c ≤ 10%

               -  Creatinine clearance (CLcr) ≥ 30 mL/min, as calculated by the Cockcroft-Gault
                  equation (using actual body weight)

          8. Subject has not been treated with any investigational drug or device within 42 days of
             the Screening visit

          9. A negative serum pregnancy test is required for female subjects (unless surgically
             sterile or women ≥ 54 years of age with cessation for 24 ≥ months of previously
             occurring menses).

             Complete abstinence from intercourse. Periodic abstinence (e.g., calendar, ovulation,
             symptothermal, post-ovulation methods) is not permitted.

             Or

             Consistent and correct use of 1 of the following methods of birth control listed
             below, in addition to a male partner who correctly uses a condom, from the date of
             Screening until 30 days after last dose of study drug:

               -  intrauterine device (IUD) with a failure rate of &lt; 1% per year

               -  female barrier method: cervical cap or diaphragm with spermicidal agent

               -  tubal sterilization

               -  vasectomy in male partner

               -  hormone-containing contraceptive:

                    -  implants of levonorgestrel

                    -  injectable progesterone

                    -  oral contraceptives (either combined or progesterone only)

                    -  contraceptive vaginal ring

                    -  transdermal contraceptive patch

         10. Subject must be able to comply with the dosing instructions for study drug
             administration and be able to complete the study schedule of assessments.

        Exclusion Criteria:

          1. Clinically-significant illness (other than HEV) or any other major medical disorder
             that, in the opinion of the investigator, may interfere with subject treatment,
             assessment or compliance with the protocol.

          2. Ribavirin administration within the last 28 days.

          3. Infection with the hepatitis C virus (defined as HCV RNA positive)

          4. Gastrointestinal disorder or post-operative condition that could interfere with the
             absorption of the study drug (for example, gastric bypass or severe ulcerative
             colitis).

          5. Difficulty with blood collection and/or poor venous access for the purposes of
             phlebotomy.

          6. Psychiatric hospitalization, suicide attempt, and/or a period of disability as a
             result of their psychiatric illness within the last 2 years. Subjects with psychiatric
             illness that is wellcontrolled on a stable treatment regimen for at least 12 months
             prior to screening or has not required medication in the last 12 months may be
             included.

          7. Significant drug allergy (such as anaphylaxis or hepatotoxicity).

          8. Pregnant or nursing female

          9. Clinically-relevant drug or alcohol abuse within 12 months of screening including any
             uncontrolled drug use within 6 months of screening. A positive drug screen will
             exclude subjects unless it can be explained by a prescribed medication; the diagnosis
             and prescription must be approved by the investigator. Uncontrolled users of
             intravenous drugs will not be permitted to enroll in the study.

         10. Use of any prohibited concomitant medications within 21 days of the Baseline/Day 1
             visit.

             Use of Amiodaron as concomitant medication is prohibited within 60 days of
             Baseline/Day1 visit.

         11. Known hypersensitivity to SOF or formulation excipients.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Markus Cornberg, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hannover Medical School, Clinic for Gastroenterology, Hepatology, and Endocrinology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Markus Cornberg, Prof. Dr.</last_name>
    <phone>+49 511 532</phone>
    <phone_ext>6821</phone_ext>
    <email>Cornberg.Markus@mh-hannover.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Svenja Hardtke, Dr.</last_name>
    <phone>+49 511 532</phone>
    <phone_ext>6057</phone_ext>
    <email>Hardtke.Svenja@mh-hannover.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hannover Medical School, Clinic for Gastroenterology, Hepatology, and Endocrinology</name>
      <address>
        <city>Hanover</city>
        <state>Lower Saxony</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Markus Cornberg, Prof. Dr.</last_name>
      <phone>0049 511 532</phone>
      <phone_ext>6821</phone_ext>
      <email>cornberg.markus@mh-hannover.de</email>
    </contact>
    <investigator>
      <last_name>Hans H. Wedemeyer, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charité, Campus Virchow-Klinikum, Medical Department, Division of Hepatology and Gastroenterology</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tobias Müller, PD Dr.</last_name>
      <phone>0049 30 450553</phone>
      <phone_ext>022</phone_ext>
      <email>tobiashp.mueller@charite.de</email>
    </contact>
    <investigator>
      <last_name>Tobias Müller, PD Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center Hamburg-Eppendorf, Center for Internal Medicine, I. Medical Clinic and Polyclinic</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sven Pischke, PD Dr.</last_name>
      <phone>0049 40 74105</phone>
      <phone_ext>7981</phone_ext>
      <email>s.pischke@uke.de</email>
    </contact>
    <investigator>
      <last_name>Sven Pischke, PD Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2017</study_first_submitted>
  <study_first_submitted_qc>September 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2017</study_first_posted>
  <last_update_submitted>February 15, 2018</last_update_submitted>
  <last_update_submitted_qc>February 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis E</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis E</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sofosbuvir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

